Chest
EditorialIntroducing the Severe Asthma Series of Invited Reviews
Cited by (0)
FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: P. A. has received research support from the National Institutes of Health and the American Partnership for Eosinophilic Disorders, has received research support and consultancy fees from and has been on advisory boards for AstraZeneca and GlaxoSmithKline, and has received research support from Regeneron. D. J. J. has received speaker fees and advisory board fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Sanofi. M. E. W. has received research support from the National Institutes of Health, has received consultancy fees from and has been on advisory boards for AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron, Genentech, Amgen, Teva, and Cohero.